Sharquie K E, Najim R A, Farjou I B, Al-Timimi D J
Department of Dermatology, College of Medicine, University of Baghdad, Baghdad, Iraq.
Clin Exp Dermatol. 2001 Jan;26(1):21-6. doi: 10.1046/j.1365-2230.2001.00752.x.
A clinical trial to evaluate the efficiency of oral zinc sulphate in the treatment of cutaneous leishmaniasis was conducted. One-hundred and four patients with parasitologically proven cutaneous leishmaniasis were included in the trial. Patients were assigned randomly to receive 2.5, 5 or 10 mg/kg of zinc sulphate orally, and a control group of patients did not receive any treatment. All patients were followed up for 45 days. At the end of the follow-up period, lesions were assessed and parasitological proof of cure or otherwise was sought. Results showed that the cure rate for the 2.5 mg/kg group was 83.9%, for the 5 mg/kg treatment group it was 93.1% and for the 10 mg/kg treatment group it was 96.9%. No lesions in the control group showed any sign of healing during the follow-up period. Therefore, oral zinc sulphate can be recommended as a very safe therapy for cutaneous leishmaniasis.
开展了一项评估口服硫酸锌治疗皮肤利什曼病疗效的临床试验。104例经寄生虫学证实患有皮肤利什曼病的患者被纳入该试验。患者被随机分配口服2.5、5或10mg/kg的硫酸锌，对照组患者不接受任何治疗。所有患者均随访45天。在随访期结束时，对皮损进行评估，并寻找治愈或未治愈的寄生虫学证据。结果显示，2.5mg/kg组的治愈率为83.9%，5mg/kg治疗组为93.1%，10mg/kg治疗组为96.9%。对照组在随访期间没有皮损显示出任何愈合迹象。因此，口服硫酸锌可被推荐为一种治疗皮肤利什曼病非常安全的疗法。
